This page catalogs biotechnology and pharmaceutical companies developing neural stem cell (NSC) transplantation, neural progenitor cell (NPC) therapies, and endogenous NSC activation approaches for Alzheimer's disease (AD). These therapies focus on cell replacement and neural circuit reconstruction, distinct from broader cell therapy approaches and molecular neurogenesis promoters.
| Category | Focus | This Page |
|---|---|---|
| Neural Stem Cell Therapy | NSC/NPC transplantation, endogenous activation | ✓ Covered here |
| Cell Therapy (Broader) | MSCs, iPSC-derived various cells, microglia | See AD Cell Therapy |
| Neurogenesis (Molecular) | Small molecules, biologics promoting neurogenesis | See AD Neurogenesis |
| Approach | Description | Companies |
|---|---|---|
| Allogeneic NSC Transplantation | Donor-derived neural stem cells for hippocampal replacement | Neuralstem, StemoniX |
| Autologous NSC Therapy | Patient-derived stem cells | Nostro Therapeutics |
| iPSC-Derived NPCs | Patient-specific neural progenitor cells | Aspen Neuroscience, Cellize |
| Endogenous NSC Activation | Activating brain's own neural stem cell niches | Neurowonder, Anagenesis |
| Neurotrophic Secreting Cells | Engineered cells producing BDNF, GDNF, NGF | Neurosphere, StemoniX |
Status: Phase 1 Completed (AD), Discovery
Neuralstem, Inc. is a pioneer in neural stem cell therapy, developing NSI-566, a human spinal cord-derived neural stem cell line. The company has completed a Phase 1 trial for AD and continues to explore NSC transplantation approaches.
Status: Preclinical
StemoniX is a biotechnology company developing microbrain® and axon® platforms for neural disease modeling and therapy. Their approach combines human iPSC-derived neural cells with proprietary aggregation technology for functional neural tissue generation.
Status: Preclinical (AD program)
Aspen Neuroscience is developing autologous iPSC-derived neural cells for AD, with a focus on cholinergic neuron replacement for basal forebrain restoration.
Status: Discovery
Cellize is a biotechnology company focused on iPSC-derived cell therapies for neurodegenerative diseases. Their platform specializes in neural progenitor cell differentiation and large-scale manufacturing.
Status: Discovery
Neurowonder Therapeutics is developing small molecule and biologic approaches to activate endogenous neural stem cells in the adult brain. Their focus is on the subventricular zone (SVZ) and subgranular zone (SGZ) niches.
Status: Preclinical
Anagenesis is developing regenerative medicine approaches for neurological disorders, with a focus on endogenous stem cell activation and tissue engineering.
Status: Discovery
Neurosphere Therapeutics is focused on developing cell-based therapies that combine neural progenitor cells with engineered neurotrophic factor expression.
| Company | Approach | Development Stage | Key Mechanism |
|---|---|---|---|
| Neuralstem | Allogeneic NSCs | Phase 1 Completed | Neuronal replacement, neurotrophic secretion |
| StemoniX | iPSC-derived NPCs | Preclinical | 3D neural spheroids, circuit reconstruction |
| Aspen Neuroscience | Autologous iPSC-NPCs | Preclinical | Cholinergic neuron replacement |
| Cellize | iPSC to NPC platform | Discovery | Controlled differentiation |
| Neurowonder | Endogenous NSC activation | Discovery | Niche pathway modulation |
| Anagenesis | Endogenous stem cell activation | Preclinical | Small molecule niche modulators |
| Neurosphere Therapeutics | NPCs + neurotrophic factors | Discovery | Combined replacement and trophic support |
| Company | Product | Phase | NCT Number | Status |
|---|---|---|---|---|
| Neuralstem | NSI-566 | Phase 1 | NCT03072134 | Completed |
This page complements and is distinct from related category pages: